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Abstract
Intensive multifactorial treatment aimed at cardiovascular (CV) risk factor reduction in type 2 diabetic patients with
microalbuminuria can diminish fatal and non-fatal CV. Plasma N-terminal (NT)-proBNP predicts CV mortality in
diabetic patients but the utility of P-NT-proBNP in screening for atherosclerosis is unclear. We examined the
interrelationship between P-NT-proBNP, presence of atherosclerosis and/or vascular dysfunction in the coronary,
carotid and peripheral arteries in asymptomatic type 2 diabetic patients with microalbuminuria that received
intensive multifactorial treatment.
Methods and Results: P-NT-proBNP was measured in 200 asymptomatic type 2 patients without known cardiac
disease that received intensive multifactorial treatment for CV risk reduction. Patients were examined for coronary,
carotid and peripheral atherosclerosis, as defined by coronary calcium score ≥400, carotid intima-media thickness
(CIMT) > 0.90 mm, ankle-brachial index < 0.90, and/or toe-brachial index < 0.64, respectively. Carotid artery
compliance was also determined and the reactive hyperaemia index (RHI) measured by peripheral artery tonometry
was used as a surrogate for endothelial function.
P-NT-proBNP was associated with atherosclerosis in the unadjusted analysis, but not after adjustment for
conventional risk factors. P-NT-proBNP was not associated with vascular dysfunction. The prevalence of
atherosclerosis in the coronary, carotid and peripheral arteries was 35%, 10% and 21% of all patients, respectively.
In total 49% had atherosclerosis in one territory and 15.6% and 1.0% in two and three territories. Low RHI was an
independent predictor of coronary atherosclerosis (odds ratio [CI], 2.60 [1.15-5.88] and systolic blood pressure was
the only independent determinant of CIMT (0.02 mm increase in CIMT per 10 mmHg increase in systolic blood
pressure [p = 0.003]).
Conclusions: Half of asymptomatic patients with type 2 diabetes mellitus and microalbuminuria had significant
atherosclerosis in at least one vascular territory despite receiving intensive multifactorial treatment for CV risk
reduction. Coronary atherosclerosis was most prevalent, whereas carotid disease was more rarely observed. RHI but
not plasma NT-proBNP was predictive of coronary atherosclerosis.
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Atherosclerosis is the most important determinant of
the excessive morbidity and mortality in type 2 diabetic
patients, especially in patients with albuminuria. Medical
treatment aimed at reduction of established cardiovascu-
lar (CV) risk factors is effective in reducing the
increased CV morbidity and mortality in diabetic
patients with microalbuminuria [1]. By enabling early
and aggressive preventive interventions, screening for
subclinical atherosclerotic disease may therefore be of
value in high risk diabetic patients.
Elevated plasma brain natriuretic peptide (P-BNP) and
N-terminal-proBNP (P-NT-proBNP) levels, released in
response to cardiomyocyte stress, are established risk
factors in patients with heart failure [2]. In addition,
minor increases in P-NT-proBNP below levels seen in
heart failure, have been associated with poor outcome in
other populations [3]. We have previously identified P-
NT-proBNP as a powerful predictor of CV mortality in
type 2 diabetic patients, independent of albuminuria [4].
The causes of the poor prognosis associated with ele-
v a t e dP - N T - p r o B N Pa r eu n c l e a rb u te l e v a t e dP - N T -
proBNP may correlate with the severity of coronary
atherosclerosis [5]. Furthermore, whether P-NT-proBNP
is associated with subclinical atherosclerotic manifesta-
tions or vascular dysfunction in the carotid or peripheral
arteries is not known in detail. Finally, if the presence of
atherosclerosis and/or dysfunction in different territories
a r ec o r r e l a t e di nt y p e2d i a b etic patients that receive
intensive multifactorial treatment, aimed on CV preven-
tion, is not known [6]. Accordingly, we examined the
interrelationship between P-NT-proBNP, presence of
atherosclerosis and/or vascular dysfunction in the cor-
onary, carotid and peripheral arteries, respectively, in
asymptomatic type 2 diabetic patients with microalbu-
minuria that received intensive multifactorial treatment.
Methods
Patient cohort and clinical measurements
In a cross-sectional study at Steno Diabetes Center, we
identified from January 2007 to February 2008, a conse-
cutive cohort of 200 asymptomatic type 2 diabetic
patients with microlbuminuria without prior known CV
disease and with normal plasma creatinine to allow for
examinations with x-ray contrast media. Diabetes was
diagnosed by the WHO criteria and all patients received
intensive multifactorial intervention aimed at optimal
glycaemic, lipid, and blood pressure control, as well as
antiplatelet therapy and lifestyle modification according
to the Steno-2 study [1]. Noteworthy, an audit com-
pared the levels of treatment targets before and after the
Steno-2 study (2002 and 2009) and demonstrated that
the Steno-2 study results of lowering haemoglobinA1c,
lipids and blood pressure were successfully implemented
into clinical practise at Steno Diabetes Center [7].
The clinical characteristics and P-NT-proBNP mea-
surements have previously been described, including our
NT-proBNP cut-off value of 45.2 ng/l, which repre-
sented the median P-NT-proBNP in the first 50 patients
examined in the study [8]. Tests for autonomic neuropa-
thy, heart rate variability assessed by the expiration-
inspiration variation of the heart rate, and orthostatic
blood pressure measurements were performed. Heart
rate variability ≤ 10 bpm and an orthostatic blood pres-
sure fall > 30 mmHg were considered abnormal.
Somatic nerve function (vibratory perception threshold)
was evaluated by biothesiometry. Smoking was defined
as persons smoking one or more cigarettes/cigars/pipes
a day, all others were classified as non-smokers.
Investigations of the coronary, carotid, and peripheral
arteries
Coronary calcium scanning was performed during a sin-
gle breath hold using a 16 multidetector-row CT scan-
ner with 3 mm slice thickness (Philips Precedence MX
8000 IDT 16 slice, Philips Medical Systems, Best, The
Netherlands). Quantification of Agatston coronary cal-
cium score (CCS) was done as previously described [9].
CCS is a continuous measurement of the coronary
arteries atherosclerotic burden and CCS is strongly cor-
related with histopathologic coronary artery disease[10
11]. Furthermore, CCS is a powerful predictor of CV
morbidity and mortality in asymptomatic diabetic and
non-diabetic populations [12]. Of note, in diabetic
patients with proteinuria a threshold (CCS≥400) for
clinical significant disease exists, and accordingly, coron-
ary atherosclerosis was defined as CCS≥400 [13].
Patients with NT-proBNP ≥ 45.2 ng/l and/or CCS ≥ 400
were further examined with myocardial perfusion ima-
ging (MPI), CT angiography (CTA) and/or coronary
angiography (CAG), but the correlations between P-NT-
proBNP, CTA, MPI and CAG have previously been
reported [8]. Therefore in the current study, the results
of the latter investigations were not used for our defini-
tion of coronary atherosclerosis (6). A common carotid
artery wall segment of 5-10 mm in length was imaged
in a longitudinal view, located approximately 20 mm
proximal to the bifurcation (Siemens Acuson Cypress
ultrasound scanner with a linear probe 7-10 MHz 7L3).
Carotid intima-media thickness (CIMT) was measured
at the posterior arterial wall. Bilateral carotid ultrasound
examination was performed and the mean CIMT of
both arteries were used. Carotid artery atherosclerosis
was defined as CIMT > 0.90 mm [14]. All images were
saved as 4- to 6-second long dynamic scans and arterial
compliance was measured with dedicated vascular
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sion 5.0; LLC, Coralville, IA, USA). Carotid vascular
function was assessed by regional vascular compliance
of the carotid arteries, using B-mode scans and calcu-
lated as previously described, i.e., carotid compliance =
(carotid diametermax
2 - carotid diametermin
2)/pulse pres-
sure [14]. Carotid compliance was expressed as arterial
distensibility adjusted for vessel size and sex.
Systolic blood pressures in the ankle and big toe were
measured on both legs by the strain gauge technique
and the lowest pressures were used for calculation of
the ankle-brachial index (ABI) and toe-brachial index
(TBI) index, respectively [15]. Peripheral artery disease
was defined as ABI < 90% and/or TBI < 64% [16].
Finally, peripheral microvascular endothelial function
and arterial stiffness were measured with a plethysmo-
graphic device (EndoPAT2000, Itamar Medical Ltd, Cae-
sarea, Israel). This test was presented to the patients as
a scientifically important but optional test since it is not
yet applicable in a clinical setting. As previously
described, a pulse wave amplitude was obtained with
pneumatic probes in both test and control index fingers
during 10 minutes rest in the supine position and again
after interrupting the brachial arterial blood flow by
inflation a blood pressure cuff (>200 mmHg) for 5 min-
utes in the test finger [17]. The reactive hyperaemia
index (RHI) and augmentation index (AI) were obtained
with computerized automated algorithm analyses. RHI
was the ratio of postdeflation to baseline pulse ampli-
tude in test finger divided by the same ratio in control
finger. RHI is dependent on endothelium-derived nitric
oxide availability and is positively correlated with both
the flow-mediated vasodilation measured in the brachial
artery and the endothelium-dependent coronary flow
reserve[18 19]. AI is defined as the difference between
the first and the second peak of the radial arterial wave-
form by return of reflected pressure waves [20]. Periph-
eral artery AI is an index of arterial stiffness, i.e., when
arteries are stiffer, wave reflections return earlier, and is
positively correlated with central arterial stiffness [21].
The study was approved by the local ethics committee
and all patients gave written informed consent.
Statistical analysis
Our primary objective was to describe if patients with
elevated NT-proBNP (and therefore poor prognosis)
have subclinical atherosclerosis and/or vascular dysfunc-
tion. Accordingly, we investigated if patients with P-NT-
proBNP levels above our previous defined cut-off value
(45.2 ng/l) had more atherosclerosis and/or dysfunction
than patients with P-NT-proBNP below this value [22].
Furthermore, we examined the associations between
atherosclerosis or vascular dysfunction and CV risk fac-
tors including P-NT-proBNP as a continuous variable in
univariate linear regression analyses and multivariate
logistic regression models with determination of unad-
justed odds ratios (ORs) and ORs adjusted for variables
associated with atherosclerosis/vascular dysfunction in
the univariate analysis. In addition, the predictive accu-
racy for presence of atherosclerosis of the covariate-
adjusted models with and without inclusion of P-NT-
proBNP were compared by generating receiver operating
characteristic (ROC) curves and the areas under the
ROC curves (AUCs) were calculated. In the above ana-
lyses, patients were divided into groups of patients with
or without atherosclerosis as determined by CCS,
CIMT, ABI and/or TBI, and subgroups including
patients with coronary, peripheral or carotid athero-
sclerosis alone, and in patients with atherosclerosis in
two or three vascular territories, respectively. Compari-
sons between groups were performed by unpaired Stu-
dent’st - t e s to ra n a l y s i so fv a r i a n c e( A N O V A ) .T h e
Pearson Chi
2-test was used to compare non-continuous
variables. Secondarily, we evaluated if cut-offs (quartile)
values of the functional vascular/atherosclerotic tests in
multivariate logistic regression were able to identify
atherosclerosis in different vascular territories but in
particular coronary atherosclerosis. Data were expressed
as means (SD), except for non-normally distributed vari-
ables, which were log10-transformed before analysis and
are given as medians (interquartile range). A P-value
less than 0.05 was considered as statistically significant.
A l ld a t aw e r ea n a l y z e db yu s i ng statistical package for
social sciences (SPSS) version 14 for Windows.
Results
Patient characteristics
The clinical characteristics of patients are summarized
in Table 1. Of note, the medical treatment for CV dis-
ease prevention included statins (94% of patients),
aspirin (90%), and renin angiotensin aldosterone system
(RAAS)-blocking agents (98%).
Plasma NT-proBNP and atherosclerosis
Patients with P-NT-proBNP above our cut-off value
(45.2 ng/l) did not have more overall atherosclerosis or
more vascular dysfunction than patients with NT-
proBNP levels below this value (p > 0.05). We did, how-
ever, demonstrate that coronary atherosclerosis was
more present in patients with P-NT-proBNP above cut-
off value (42 vs. 26 patients p = 0.041). Furthermore, P-
NT-proBNP levels were higher in patients with athero-
sclerosis in one vascular territory (median [interquartile
range]; 47.5 [23.1-83.8] ng/l) and in patients with ather-
osclerosis in two or three vascular territories (90.6 [25.3-
227.5 ng/l]) compared to patients without atherosclero-
sis (32.6 (12.7-95.0) ng/l, p = 0.005). However, after
adjustments for age and gender these associations were
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proBNP to the ROC curve for prediction of athero-
sclerosis did not increase the AUC (78.4% vs. 78.4%, not
shown).
Atherosclerosis in different vascular territories:
Prevalences and risk factors
Although a few patients were not examined with all
investigative modalities due to technical difficulties, CCS
was obtained in 98% (195/200) of patients and ultraso-
nography of the common carotid artery was performed
in 92% (183/200) of patients, including a bilateral exami-
nation in 77% (147/200) of patients. Peripheral systolic
blood pressure including a toe pressure was measured
in 97% (193/200) and peripheral artery tonometry was
performed in 83.5% (167/200) of patients. We
experienced no technical problems with the latter test
but some patients declined this procedure.
In total, 173 patients had examinations of all three
vascular territories and among these patients 49.1% (85/
173) had abnormalities indicative of atherosclerosis as
defined in the current study, in at least one territory. Of
the 27 patients excluded in this analysis, all patients but
one patient had 2 vascular investigations performed,
including 10 and 16 patients with or without signs of
atherosclerosis, respectively. The clinical characteristics
and results of the vascular measurements in all patients
(n = 200) and in patients that underwent all three inves-
tigations (n = 173) are summarized in Table 2. In a
multivariate logistic regression model, including risk fac-
tors associated with atheroscl e r o s i s ,i . e . ,a g e ,s e x ,d i a -
betes duration, smoking, retinopathy, body mass index
Table 1 Clinical characteristics in 200 type 2 diabetic patients and in 173 patients with or without atherosclerosis,
including coronary calcium score (CCS) ≥400, ankle-brachial index (ABI) < 0.90 and/or toe-brachial index (TBI) < 0.64
and/or carotis intima-media thickness (CIMT) > 0.90 mm, respectively
All patients
(n = 200)
Patients with atherosclerosis
(n = 85) ^
Patients without atherosclerosis
(n = 88) ^
p-values
Sex no. (male%) 152 (76) 73 (86) 59 (67) 0.004
Age (years) 59 (9) 62 (5) 55 (9) <0.001
Duration of diabetes (years) 13 (7) 14 (7) 11 (7) 0.001
BMI (kg/m
2) 32.6 (5.8) 31.5 (5.3) 33.5 (6.2) 0.029
HbA1c (%) 7.9 (1.3) 7.8 (1.2) 7.9 (1.5) 0.62
Urinary albumin excretion rate (mg/24h)* 103 (39 - 230) 98 (33-293) 87 (44-191) 0.85
P-creatinine (μmol/l) 76 (18) 79 (18) 74 (18) 0.13
Systolic blood pressure (mmHg) 130 (17) 132 (18) 128 (16) 0.16
Total cholesterol (mmol/l) 3.9 (0.9) 3.9 (1.0) 4.0 (0.9) 0.58
Heart rate variation during deep
breathing (bpm)*
7 (4.5-11.5) 6 (4-9) 8 (5-13) 0.013
Current smoker no. (%) 59 (30) 31 (36) 19 (22) 0.031
Vibratory perception threshold mV - mean of both
sides
33 (15) 36 (14) 30 (15) 0.004
Retinopathy no. (%) 120 (60) 57 (67) 41 (48) 0.010
Abnormal heart rate variation during deep
breathing no. (%)
118 (59) 61 (72) 51 (58) 0.015
Ortostatic hypotension no. (%) 15 (7.5) 8 (9) 6 (7) 0.055
Oral antidiabetic medication no. (%) 170 (85) 70 (82) 76 (86) 0.47
Insulin treatment no. (%) 124 (62) 56 (67) 51 (58) 0.28
RAAS blockade no. (%) 196 (98) 82 (96) 87 (99) 0.30
Statin therapy no. (%) 189 (95) 78 (92) 85 (97) 0.20
Aspirin therapy no. (%) 183 (92) 79 (93) 82 (93) 0.95
Beta-blocker therapy no. (%) 27 (14) 14 (16) 11 (13) 0.46
Calcium channel blockers no. (%) 80 (40) 36 (41) 30 (35) 0.26
Use of diuretics no. (%) 128 (64) 58 (66) 53 (62) 0.27
NT-proBNP (ng/l) * 48.7 (18.6-95.0) 44.2 (24.5-108.5) 31.9 (12.7-95.0) 0.021
NT-proBNP > 45.2 (ng/l) no. (%) 104 (52) 49 (58) 40 (45) 0.11
NT-proBNP ≤ 45.2 (ng/l) no. (%) 96 (48) 36 (42) 48 (55) 0.11
Data are expressed as means (SD) or medians (interquartile range) *, nr = not relevant,
aOur plasma NT-proBNP (45.2 ng/l) cut-off has previously been described
[8],. ^ In five, seven and 17 patients CCS, peripheral systolic blood pressure and CIMT were not measured respectively, and we only included patients with
structural tests in all three territories (173/200).
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NT-proBNP, age (OR [CI] 1.14 [1.06-1.22]), sex (male,
4.31 [1.60-11.88]) and diabetes duration (1.07 [1.00-
1.14]) remained independent predictors of
atherosclerosis.
Coronary atherosclerosis as defined by CCS≥400 was
found in 34.9% (68/195) of patients and these patients
were older (mean age 63 vs. 57 years, p = 0.0001), more
often males (85% vs. 71% p = 0.025), and had longer
diabetes duration (15 vs. 12 years, p = 0.003), more reti-
nopathy (p = 0.045), higher vibratory perception thresh-
old (38 vs. 31 mV, p = 0.002) and higher P-NT-proBNP
(median values 64.4 vs. 42.4 ng/l, p = 0.006) compared
with patients with CCS < 400. In a multivariate logistic
regression analysis including the above variables, only
age remained independently associated with coronary
atherosclerosis.
Carotid atherosclerosis as defined by CIMT > 0.90
mm was found in 10.4% (19/183) of patients and here
only age (68 vs. 58 years, p = 0.015) was significantly
increased compared to patients without disease in this
vascular territory. However in a linear regression analy-
sis with CIMT as the dependent variable, weak associa-
tions were found between CIMT and patient age (R =
0.30, p = 0.0001), systolic blood pressure (R = 0.22, p =
0.003), vibratory perception threshold (R = 0.18, p =
0.016), heart rate variability (-R = 0.15, p = 0.053), pre-
sence of retinopathy (R = 0.17, p = 0.019, toe-brachial
index (R=-0.22, p = 0.002), P-NT-proBNP (R = 0.19, p =
0.009) and CCS (R = 0.19, p = 0.009). Including these
variables in multivariable linear regression analysis, only
systolic blood pressure was significantly associated with
CIMT, with a 0.015 mm increase in CIMT for every 10
mmHg increase in systolic blood pressure (p = 0.027).
Furthermore, a borderline non-linear relationship
between CIMT and diabetes duration was found, i.e.,
when dividing diabetes duration in to quartiles (<7,7-12,
12-18, and > 18 years), means of CIMT were 0.697,
0.743, 0.773, and 0.709 mm (ANOVA, p = 0.054),
respectively.
Peripheral artery disease as defined by ABI < 90% and/
or TBI < 64% was demonstrated in 20.7% (40/193) of
patients and in addition to the associations also seen
between certain risk factors (age, sex, duration, vibratory
perception threshold, and P-NT-proBNP) and coronary
atherosclerosis, these patients also had higher P-creati-
nine (80.3 vs. 74.2 μmol/l, p = 0.052), lower heart rate
variability (median 5 vs. 8 bpm, p = 0.003) and lower
BMI (30.3 vs. 32,7 kg/m2, p = 0.02) compared to
patients without peripheral atherosclerosis. In a multi-
variate logistic regression model, including above-men-
tioned risk factors, only BMI was independently
associated with peripheral artery disease, (p = 0.045).
Interrelations between atherosclerosis in different
vascular territories
Among 56 patients with atherosclerosis in only one vas-
cular territory (Figure 1), no differences in risk factors
were demonstrated when comparing patients with cor-
onary, carotid, and peripheral atherosclerosis (ANOVA,
p > 0.05). As shown in Figure 1, only 15.6% (29/173) of
patients had atherosclerosis in at least two territories,
including 2 patients with atherosclerosis in all three ter-
ritories. Patients with atherosclerosis in two or three ter-
ritories only had higher vibratory perception threshold
( 4 2v s .3 3m V ,p=0 . 0 1 3 )c o m p a r e dt op a t i e n t sw i t h
atherosclerosis in only one territory, while the other risk
factors were comparable between groups. The level of
Table 2 Atherosclerosis measurements in 200 type 2 diabetic patients and in 173 patients with or without
atherosclerosis, including coronary calcium score (CCS) ≥400, ankle-brachial index (ABI) < 0.90 and/or toe-brachial
index (TBI) < 0.64 and/or carotis intima-media thickness (CIMT) > 0.90 mm, respectively
All patients
(n = 200)
Patients with atherosclerosis
(n = 85) ^
Patients without atherosclerosis
(n = 88) ^
p-values
Coronary Calcium Score* 183 (6-604) 552 (256-1369) 12 (0-115) nr
Carotid intima-media thickness (mm) 0.73 (0.15) 0.79 (0.17) 0.68 (0.10) nr
Carotid function
a (l/mmHg) 0.0026 (0.001) 0.0024 (0.001) 0.0027 (0.001) 0.073
Toe-brachial index (%) 121 (34) 75 (23) 100 (17) nr
Ankle-brachial index (%) 108 (17) 98 (19) 114 (11) nr
Pulse pressure wave augmentation
b* 5 (-2-12) 8 (0-14) 3 (-5-10?) 0.076
Reactive hyperemia index
c 1.70 (0.44) 1.64 (0.42) 1.75 (0.47) 0.14
Reactive hyperemia index ≤1.43
^^ 45 (27) 26 (33) 14 (20) 0.007
Reactive hyperemia index > 1.43
^^ 122 (73) 43 (55) 64 (93) 0.007
CAD
d no. (%) 70 (35) 44 (52) 16 (18) <0.001
Data are expressed as means (SD) or medians (interquartile range) *, nr = not relevant,
acarotid distensibility measured with a ultrasound scanner, peripheral
microvascular endothelial function measured as
bradial augmentation index or
creactive hyperemia index, both measured with a plethysmographic device.
d
Significant coronary artery disease (CAD) as defined by myocardial perfusion imaging and coronary angiography and previous described [8]. ^ In five, seven and
17 patients CCS, peripheral systolic blood pressure and CIMT were not measured respectively, and we only included patients with structural tests in all three
territories (173/200). ^^ Reactive hyperemia index was performed in 167/200 patients and 147 of the 167 patients also had all three structural tests performed.
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sis in any vascular territory.
Peripheral artery disease was not directly related with
atherosclerosis in the coronary territory (Figure 1).
Although atherosclerosis was confined to one vascular
territory in the majority of cases, patients with athero-
sclerosis in one territory had significantly higher risk of
having disease in another territory, i.e., unadjusted and
adjusted (for age, sex, diabetes duration, retinopathy,
vibration threshold, and P-NT-proBNP) ORs for coron-
ary atherosclerosis were 3.52 (1.89-8.11) and 2.62 (1. 20-
5.974) in patients with peripheral artery disease, and
unadjusted and adjusted (for age, sex, diabetes duration,
P-creatinine, heart rate variability, BMI, vibration
threshold, and P-NT-proBNP) ORs of peripheral artery
disease were 3.92 (1.89-8.11) and 3.38 (1.46-7.81) in
patients with coronary atherosclerosis.
Peripheral vascular function and carotid distensibility
RHI and AI measured by peripheral artery tonometry
and data on carotid distensibility assessed by ultrasound
examination are shown in Table 1. AI and carotid dis-
tensibility did not differentiate between atherosclerosis
vascular territories and extent of the disease (1, 2 or 3
territories), but with use of a cut-off value, RHI was
found to contain important differential information.
When RHI was divided into quartiles and patients in
the lower quartile (RHI ≤1.43 [low RHI], n = 45) were
compared with patients in the other quartiles (normal
RHI, n = 122) in multivariate logistic regression analyses
with coronary atherosclerosis or peripheral artery dis-
ease, or the number of diseased vascular territories as
dependent variables, respectively, and adjustments were
made for the previously described risk factors, low RHI
was independently associated with coronary artery
atherosclerosis (OR 2.60 [1.15-5.88]), peripheral artery
disease (OR 3.60 [1.45-8.95]), and atherosclerosis in any
vascular territory ( OR 3.28 [1.30-8.25]). It is note-
worthy, that when the presence of peripheral artery dis-
ease was included in the predictive model, low RHI
remained independently predictive of coronary athero-
sclerosis (p = 0.04). The prevalences of low and normal
RHI in patients with or without atherosclerosis are
shown in Table 1. Among patients with atherosclerosis
in two or three vascular territories, 48% had low RHI
compared to 33% in patients with atherosclerosis in one
territory (p = 0.23). In addition, 72% of the patients with
normal RHI were free of coronary atherosclerosis (p =
0.022) and in patients with normal RHI or age below 57
(the 1
st age tertile) years (n = 40), 95% were without
coronary atherosclerosis (p < 0.001). In contrast, age
below 57 years alone excluded coronary atherosclerosis
in 84% of patients (p < 0.001).
Discussion
Principal findings
Our primary objective was to describe if type 2 diabetic
patients with microalbuminuria and with elevated NT-
proBNP (and therefore poor prognosis) have subclinical
atherosclerosis and/or vascular dysfunction. NT-proBNP
levels were not related with vascular dysfunction, and
although NT-proBNP levels were significantly associated
with the presence and extent of atherosclerosis, we
demonstrated no independent associations after adjust-
ments for age and sex. Secondarily, we determined the
prevalence of atherosclerosis in 200 asymptomatic type
2 diabetic patients with microalbuminuria but without
known CV disease and with normal plasma creatinine.
Among these patients that received intensive multifac-
torial treatment aimed at CV risk reduction, almost half
of subjects had atherosclerosis in at least one vascular
territory, and 15% and 1% had atherosclerosis in two
and three territories including coronary, carotid and
peripheral arteries, respectively. Furthermore, we found
that carotid atherosclerosis was rarely observed (10%)
and was independently associated with the systolic
blood pressure, whereas coronary atherosclerosis was
more prevalent (35%) and was associated with low RHI
measured by peripheral tonometry.
Increased NT-proBNP and atheroslcerosis
We have previously demonstrated a strong and indepen-
dent risk for CV mortality with elevated P-NT-proBNP
in type 2 diabetic patients [4]. In the present study,
however, no independent relationship was found
between P-NT-proBNP and atherosclerosis. Several fac-
tors may contribute to this finding. First, patients in this
study were asymptomatic and had normal P-creatinine
wheareas subjects in our earlier study were all type 2
diabetic patients (e.g., including cases with CV disease
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Figure 1 Venn diagram showing the relationship between
cardiovascular disease manifestations in different territories in
85 type 2 diabetic patients with microalbuminuria.
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clinic (4). Second, the increasingly intensive treatment
used today in our patients is likely to have influenced
the results compared to the earlier study, although in
the Steno 2 multifactorial intervention study, P-NT-
proBNP remained a strong independent predictor of CV
mortality and here NT-proBNP levels also increased
over time in the intervention group [23].Third, other
factors than atherosclerosis per se, e.g., cardiac auto-
nomic neuropathy or echo abnormalities are likely to
influence CV mortality. Along this line, it has been
demonstrated that half of asymptomatic type 2 diabetes
patients have left ventricular diastolic dysfunction and
that BNP is associated with presence of diastolic dys-
function [24]. Actually, BNP is a useful tool for screen-
ing preclinical moderate-severe diastolic dysfunction,
which could be irrespective of age and obesity[25 26]. In
addition measuring NT-proBNP before non cardiac sur-
gery in clinical practice is useful to risk stratify patients
[27]. Finally, BNP is also a sensitive and specific biomar-
ker for the detection of systolic dysfunction in the gen-
eral population [28].
Multifactorial treatment and subclinical atherosclerosis
Intensive individual and multifactorial interventions
including polypharmacologic therapy according to inter-
national guidelines is the current standard of care in our
institution and is known to reduce CV morbidity and
mortality [1]. Noteworthy, an audit compared the levels
of treatment targets before and after the Steno-2 study
(2002 and 2009) and demonstrated that the Steno-2
study results of lowering haemoglobinA1c, lipids and
blood pressure were successfully implemented into clini-
cal practise at Steno Diabetes Center [7]. Almost all
patients in the current study received statins, aspirin
and RAAS blockading agents, and 33%, 28%, and 17%
received 2, 3, and ≥4 antihypertensive drugs on top of
RAAS blockade. Indeed, this intensive treatment yielded
mean total cholesterol levels of 3.9 mM, arterial blood
pressures of 130/75 mmHg, and haemoglobinA1c levels
of 7.9%, respectively, which may explain why most of
the conventional CV risk factors as well as albuminuria
were not associated with atherosclerosis in our study.
At birth CIMT is 0.5 mm and with time CIMT
increases which is accelerated in the presence of CV
risk factors. A novel finding of the current study was
the low prevalence of carotid artery atherosclerosis in
our patients, i.e., CIMT > 0.9 mm in 10.4% and CIMT >
1.0 mm in 4.6% of patients (not shown), which is likely
to be the consequence of the year-long multifactorial
treatment aimed at CV risk reduction. For example, in a
recent study of 305 type 2 diabetic patients (mean age
58.6 years and 54.4% males) referred to a diabetes clinic
for the first time with less than 5 years of diabetes
duration and without CVD, CIMT > 1.0 mm was
observed in 35% of subjects and the average CIMT was
0.82 mm [6]. The latter study also included a non-dia-
betic reference group with an average CIMT comparable
to our patients (0.72 mm vs. 0.73 mm). Furthermore,
the METEOR trial showed that CIMT increased 0.0131
mm/year in type 2 diabetic patients compared to non-
diabetic subjects but in diabetic patients on statin ther-
apy CIMT regressed 0.0014 mm/year [29]. In addition
10 trials including 3.443 nondiabetic and diabetic indivi-
duals have shown that statin therapy significantly
reduced the progression of carotid atherosclerosis [30].
In a large cross-sectional observational population study,
the average CIMT among subjects without risk factors
was 0.712 mm in men and 0.682 mm in women, while
in subjects with 1 CV risk factor and mean age of 61
years, CIMT was 0.765 mm [31]. Our subjects were on
average 59 years of age with diabetes duration of 13
years and all had albuminuria in addition to several
other CV risk factors. With longer diabetes duration
CIMT increased although a decline was seen in those
with the longest diabetes duration probably because of
the selection force of the excess mortality in this group.
Our observed prevalences of coronary and peripheral
artery disease were higher (34% and 20%) than pre-
viously reported (19% and 15%) in asymptomatic but
less complicated diabetics [32 33]. Age was an indepen-
dent determinant of coronary atherosclerosis, and as
also found in our study, diabetes duration is a known
determinant of peripheral artery disease [34]. Our
patients with peripheral atherosclerosis had indepen-
dently increased risk of coronary atherosclerosis and
vice versa. Autopsy studies in the general population
have demonstrated a close relationship between the pre-
sence of atherosclerosis in the three vascular territories
[35 36] but as in accordance with a recent study, a high
percentage of our patients (56/85 = 66%, Figure 1) with
coronary, carotid and/or peripheral atherosclerosis
demonstrated exclusively one diseased vascular territory
[6]. Therefore these relations were not strong enough to
examine only one artery territory and then identify all
cases with atherosclerosis in the different territories.
Vascular dysfunction
Peripheral pulse pressure wave augmentation and caro-
tid compliance were not associated with NT-proBNP or
CCS, CIMT and PAD. Noteworthy, we found that a low
RHI determined by peripheral artery tonometry was an
independent predictor of coronary atherosclerosis, and
the RHI has been shown to be positively correlated with
the endothelium-dependent coronary flow reserve [18].
In the latter study, a RHI cut-off value of < 1.35, i.e.,
comparable RHI ≤1.43 used in the current study, was
particularly useful for determination of patients with
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the Framingham offspring cohort, it was also recently
shown that the RHI was associated with conventional
and metabolic CV risk factors [17]. Our study confirms
and extends these findings and provides evidence of a
potential usability of a normal RHI for selection of
asymptomatic diabetes patients at low risk of coronary
atherosclerosis. Although coronary atherosclerosis as
defined by CCS≥400 is a strong and independent CAD
predictor, the examination is costly and associated with
radiation exposure. Furthermore, only one third of our
patients had coronary atherosclerosis defined by
CCS≥400, and our results suggest that the RHI may
contribute significantly to coronary atherosclerosis
screening in these patients.
Clinical implications
Microalbuminuria is associated with micro- and macro-
angiopathy and its presence is a well-established CV risk
marker in type 2 diabetic patients [37]. Furthermore,
previous studies suggest that NT-proBNP identifies a
subgroup of patients with increased CV risk, indepen-
dent of levels of microalbuminuria [4]. As discussed
above, our present study did not demonstrate that NT-
proBNP could be used as an independent biomarker in
the detection of subclinical atherosclerosis. We did,
however, discuss the potential use in the detection of
subclinical left ventricular dysfunction based on other
recent studies. In contrast, we suggested normal RHI for
selection of patients at low risk of coronary athero-
sclerosis. Finally, our finding that more than half of our
asymptomatic patients had signs of atherosclerosis
despite intensive multifactorial treatment, is interesting.
However, although coronary, carotid and peripheral
atherosclerosis are known to be strong predictors of CV
mortality in diabetic patients [38 39 40], the true clinical
impact of the presence of atherosclerosis in different
vascular territories in our present cohort of aggressively
treated patients will be examined by planned prospective
follow-up.
Strengths and limitations
Our cohort is relatively selected, but this patient group
is expected to have excess mortality compared to the
general population. In five, seven and 17 patients CCS,
peripheral systolic blood pressure and CIMT were not
measured respectively, but we only included patients
with available structural tests in the respective terri-
tories. We used a definition of atherosclerosis that was
dependent on well-established and reasonably accurate
non-invasive investigative modalities [14 16 41]. Specifi-
cally, CCS is a continuous variable reflecting the coron-
ary artery atherosclerotic burden. Coronary
atherosclerosis is, therefore, not unequivocally defined
by CCS ≥400 but evidence suggests that this cut-off
value defines clinical significant disease in diabetic
patients with proteinuria [13]. CIMT was measured
bilaterally as recently recommended [14]. Also, since
determination of peripheral artery disease by ABI < 90%
may not be sufficiently accurate in diabetic patients due
to increased risk of peripheral arterial calcification lead-
ing to non-compressible arteries and nonvalid ABI mea-
surements, TBI was also measured in all our patients
[16]. RHI measured by peripheral artery tonometry is a
well-established marker of peripheral microvascular
endothelial function, that is associated with brachial and
coronary artery endothelial function [18].
Conclusion
Half of our asymptomatic patients with type 2 diabetes,
albuminuria and normal P-creatinine, had atherosclero-
sis in one or more vascular territories despite receiving
intensive multifactorial treatment aimed at CV risk
reduction. In this cohort, patients with elevated P-NT-
proBNP did not have more subclinical atherosclerosis,
and although P-NT-proBNP was increased in patients
with multiple atherosclerotic lesions it was not an inde-
pendent CV risk factor. Reactive hyperaemia index
determined by peripheral arterial tonometry showed
potential for coronary atherosclerosis screening.
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